iCAD Inc  

(Public, NASDAQ:ICAD)   Watch this stock  
Find more results for ICAD
9.18
-0.01 (-0.08%)
Real-time:   1:57PM EDT
NASDAQ real-time data - Disclaimer
Currency in USD
Range 9.07 - 9.25
52 week 5.94 - 11.63
Open 9.25
Vol / Avg. 23,288.00/71,427.00
Mkt cap 144.51M
P/E     -
Div/yield     -
EPS -0.18
Shares 15.67M
Beta 1.22
Inst. own 46%
Jul 28, 2015
Q2 2015 ICAD Inc Earnings Release (Estimated) Add to calendar
Apr 30, 2015
Q1 2015 iCAD Inc Earnings Call
Apr 30, 2015
Q1 2015 iCAD Inc Earnings Release
Mar 11, 2015
iCAD Inc at ROTH Conference
Feb 24, 2015
Q4 2014 iCAD Inc Earnings Call
Feb 24, 2015
Q4 2014 iCAD Inc Earnings Release
More events from DailyFinance »    

Key stats and ratios

Q1 (Mar '15) 2014
Net profit margin -14.05% -2.30%
Operating margin -9.68% -0.20%
EBITD margin - 9.88%
Return on average assets -8.46% -1.32%
Return on average equity -11.98% -2.40%
Employees 144 -
CDP Score - -

Address

98 Spit Brook Rd Ste 100
NASHUA, NH 03062-5737
United States - Map
+1-603-8825200 (Phone)
+1-603-8803843 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

iCAD, Inc. (iCAD) is an advanced image analysis and workflow solutions that enable healthcare professionals to serve patients by identifying pathologies and the most prevalent cancers. The Company has two reportable segments Cancer Detection (Detection) and Cancer Therapy. The Detection segment consists of its advanced image analysis and workflow products offering a comprehensive range of high-performance, upgradeable Computer-Aided Detection (CAD) systems and workflow solutions for mammography, Magnetic Resonance Imaging (MRI) and Computed Tomography CT. In the Therapy segment consists of its radiation therapy (Axxent) products, physics and management services, development fees, supplies, and the right to use the AxxentHub software platform. It offers an isotope-free cancer treatment platform technology. The Xoft Electronic Brachytherapy System (Xoft eBx) can be used for the treatment of early- stage breast cancer, endometrial cancer, cervical cancer and skin cancer.

Officers and directors

Lawrence Howard Chairman of the Board
Age: 62
Bio & Compensation  - Reuters
Kevin C. Burns President, Chief Financial Officer, Chief Operating Officer
Age: 44
Bio & Compensation  - Reuters
Kenneth M. Ferry Chief Executive Officer, Director
Age: 61
Bio & Compensation  - Reuters
Trading Activity - Yahoo Finance
Stacey M. Stevens Senior Vice President - Marketing and Strategy
Age: 47
Bio & Compensation  - Reuters
Jonathan Go Senior Vice President - Research and Development
Age: 52
Bio & Compensation  - Reuters
Robert L. Goodman M.D. Director
Age: 74
Bio & Compensation  - Reuters
Rachel Brem M.D. Independent Director
Age: 56
Bio & Compensation  - Reuters
Anthony F. Ecock Independent Director
Age: 53
Bio & Compensation  - Reuters
Steven N. Rappaport Independent Director
Age: 66
Bio & Compensation  - Reuters
Somu Subramaniam Independent Director
Age: 60
Bio & Compensation  - Reuters